Moderna May 7, 2026 Phase 3 trial finds Moderna mRNA flu vaccine outperforms standard vaccine in older adults - CIDRAP
Moderna May 5, 2026 Boston biotech firms back new effort to preserve U.S. edge in life sciences - The Business Journals
Moderna May 4, 2026 Vertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues - Fierce Biotech
Moderna May 4, 2026 Biopharma bites: Tolerability sinks Vertex-Moderna's CF candidate, Takeda's immune win, and more from Amgen, Latus - FirstWord Pharma
Moderna May 1, 2026 Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna Apr 30, 2026 Moderna loses key mRNA patent in European vaccine fight - Life Sciences Intellectual Property Review
Moderna Apr 28, 2026 Moderna Deploys Salesforce Agentforce Life Sciences to Unify Global Commercial Operations - HIT Consultant
Moderna Apr 28, 2026 CureVac targets Moderna with 10-patent suit over Spikevax - Life Sciences Intellectual Property Review
Moderna Apr 22, 2026 Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - BioPharma Dive
Moderna Apr 22, 2026 Moderna launches mRNA bird flu vaccine trial after HHS cancels funding - The Washington Post
Moderna Apr 21, 2026 Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Moderna Apr 20, 2026 Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNEXSPIKE - Fierce Pharma
Moderna Apr 20, 2026 Is It Too Late To Consider Moderna (MRNA) After A 114% One Year Surge? - simplywall.st
Moderna Apr 19, 2026 Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story - Yahoo Finance